ADVERTISEMENT

Income Tax department searches premises of Dolo-650 makers

July 06, 2022 08:04 pm | Updated 08:47 pm IST - Bengaluru:

Officials said the department is looking at financial documents, balance sheets and business distributor networks of Micro Labs Ltd

A pack of Dolo-650 tablets. Photo: Special Arrangement

The Income Tax department Wednesday conducted searches at the premises of Bengaluru-based pharmaceutical company Micro Labs Ltd, the manufacturers of Dolo-650 tablet that was widely used by COVID-19 patients during the last over two years, on charges of alleged tax evasion.

ADVERTISEMENT

Officials said the department is looking at financial documents, balance sheets and business distributor networks of the company as part of the searches.

The PTI has sent queries on the action to the company and a response is awaited.

ADVERTISEMENT

Some other linked locations of the company in other cities and those of its promoters and distributors are also being covered, they said.

The company said on its website that it was engaged in the making and marketing pharmaceutical products and APIs (Active Pharmaceutical Ingredients) and has 17 manufacturing units across the country apart from conducting business overseas.

Its major pharma products are Dolo-650, Amlong, Lubrex, Diapride, Vildapride, Olmat, Avas, Tripride, Bactoclav, Tenepride-M and Arbitel.

ADVERTISEMENT

Dolo-650, an analgesic (pain killer) and antipyretic (fever-reducing) was being prescribed by doctors and medical shop owners for coronavirus patients to reduce pain and fever, common symptoms caused by Covid.

In the words of the company, Dolo-650, is "virtually a household name across the country".

The company website showcased a news article, published in February, on its website that said: "The company has sold 350 crore tablets (of Dolo-650) since the Covid-19 outbreak in 2020, and earned revenues of Rs 400 crore in a year." 

The CMD of the company, Dilip Surana, has been quoted in the story.

This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
This is your last free article.

ADVERTISEMENT

ADVERTISEMENT